Peppermint
Essential peppermint oil, inhaled or as an enteric-coated capsule, in studies mainly relieved nausea and irritable bowel symptoms.
We evaluated 146 human studies on Peppermint, including 55 randomised controlled trials and 17 meta-analyses or systematic reviews; the controlled studies include 4,562 participants in total. As of 24 October 2026.
1. What Is Peppermint? Occurrence, Origin and Forms
Peppermint is a cultivated mint species in the Lamiaceae family. Its leaves and the essential oil obtained from them are used above all. Traditionally it serves as a tea and as an oil, among other things for digestive complaints and for external application.
Peppermint grows in temperate climates and is cultivated worldwide in gardens and in field cultivation. The leaves and the essential oil of the plant are used.
The essential oil is produced by steam distillation of the leaves; for tea the leaves are dried. Studies examine above all tea, essential oil, enteric-coated capsules and leaf extracts.
Forms and Preparations Studied
- Peppermint tea (infusion of dried leaves)
- Peppermint essential oil
- Enteric-coated peppermint oil capsules
- Peppermint leaf extract
- Topical preparation (gel or solution)
Not covered on this page:
- Other mint species such as spearmint (Mentha spicata)
- Isolated menthol as a single substance
- Other Lamiaceae such as lemon balm or sage
- Peppermint flavourings without peppermint constituents
2. What Does Peppermint Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Nausea | mixed | high | 1 meta-analyses · 14 controlled · 11 other | 884 |
| Irritable bowel syndrome | mixed | high | 5 meta-analyses · 5 controlled · 32 other | 783 |
| Cognition and alertness | mostly improved | moderate | 0 meta-analyses · 3 controlled · 3 other | 190 |
| Headache and Migraine | mostly no difference | low | 0 meta-analyses · 2 controlled · 1 other | 166 |
| Physical performance | mostly no difference | low | 0 meta-analyses · 2 controlled · 1 other | 21 |
| Functional dyspepsia | mostly improved | low | 0 meta-analyses · 1 controlled · 9 other | 60 |
| Respiratory tract and common cold symptoms | mostly no difference | unclear | 0 meta-analyses · 1 controlled · 2 other | 106 |
| Other investigations | mixed | high | 2 meta-analyses · 41 controlled · 36 other | 2,931 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Peppermint and Nausea: Human Studies
After operations, inhaled essential peppermint oil reduced nausea more than the control in several randomized controlled trials, for example after heart, cervical spine and thyroid operations 485773. In breast cancer patients undergoing chemotherapy, ingested peppermint extract drops relieved nausea, vomiting and loss of appetite more than water 44. Nausea and vomiting also occurred less often in randomized controlled trials 374857. The need for anti-nausea medication decreased in randomized controlled trials after cervical spine operations and after knee replacement 4872. A meta-analysis on inhalation of peppermint oil found less postoperative nausea, reduced symptoms in pregnancy-related nausea and a reduction in symptoms in chemotherapy-induced nausea 12. In pregnant women with nausea, inhaled peppermint oil did not relieve symptoms more than placebo 58. After knee replacement, nausea severity remained the same with peppermint scent as with saline solution 72. Peppermint drops taken before a nasal operation lowered the frequency of nausea, but not of vomiting 45. For peppermint tea or enteric-coated capsules, there is no separate controlled test in this area.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Wang et al. 2025 | meta-analysis · 2,062 participants | Peppermint extract (among 15 plant substances); vs. Standard treatment | Nausea: unclear |
| 9 Jin et al. 2026 | meta-analysis · 336 participants | Essential oil-based interventions, including inhalation aromatherapy and oral peppermint extract; acute phase within 24 h after chemotherapy; vs. control conditions | acute nausea severity: improved (SMD = -0.49, 95% CI -0.76 to -0.22); vomiting frequency: no difference (SMD = -0.25, 95% CI -0.75 to 0.25); vomiting severity/score: improved (SMD = -0.31, 95% CI -0.59 to -0.03) |
| 10 Mascarenhas et al. 2025 | meta-analysis | Aromatherapy with essential oils, including peppermint/mint; vs. Conventional treatment, other complementary therapies, or placebo | Nausea and vomiting: improved (SMD = -0.92; 95 % CI: -1.09, -0.74) |
| 12 Gergő et al. 2025 | meta-analysis | Peppermint oil inhalation; 2 to 96 hours after intervention; vs. Control | Nausea 2–6 h after intervention (PONV): improved (MD: -0.60 points, 95% CI: -0.77 to -0.44, p = 0.004); Symptom severity at 48 h (NVP): improved (MD: -0.51, 95% CI: -0.78 to -0.24, p = 0.015); Symptom severity at 96 h (NVP): improved (MD: -0.68, 95% CI: -1.09 to -0.27, p = 0.019) |
| 14 Wang et al. 2024 | meta-analysis | Aromatherapy with peppermint oil, ginger essence, lavender; vs. Control/standard care | Severity of postoperative nausea: improved (SMD: -0.93, 95% CI: -1.64 to -0.22; P = 0.010); Vomiting episodes: no difference (SMD: -0.81, 95% CI: -1.98-0.37; P = 0.180) |
| 15 Ahn et al. 2024 | meta-analysis | Aromatherapy, including peppermint oil (inhalation, massage); vs. Control groups of included RCTs | Overall nausea and vomiting: improved (SMD = -0.81, 95 % CI: -1.11 to -0.52); Nausea: improved (SMD = -0.85, 95 % CI: -1.23 to -0.46); Combined nausea and vomiting: improved (SMD = -1.08, 95 % CI: -1.68 to -0.47) |
| 34 Ahmadi et al. 2020 | randomised controlled · 120 participants | Inhalation of 10% or 30% peppermint essential oil; 0.2 ml of 10% or 30% peppermint oil; Single application, measured after 10 minutes; vs. Distilled water with green food coloring | Nausea severity (NVAS): unclear (52.3 ± 13.7 auf 40.5 ± 13.5 (p < 0.001)); Nausea severity (NVAS): unclear (60.2 ± 15.0 auf 39.7 ± 12.4 (p < 0.001)); Nausea severity (NVAS): unclear |
| 37 Tang et al. 2026 | randomised controlled · 106 participants | Inhalation with 2% peppermint oil; 2% peppermint oil, inhalation; before induction, preoperatively, immediately after extubation; vs. 2 ml 0.9% sodium chloride inhalation | Incidence of PONV within 24 h: improved (52.8% vs. 73.6%; p = 0.043); Incidence of PONV during the first hour: improved (45.3% vs. 73.6%; p = 0.047) |
Further studies in this area: 39 41 44 45 48 49 57 58 66 72 73 80 85 87 99 111 132 137
Peppermint and Irritable Bowel Syndrome: Human Studies
In irritable bowel syndrome, peppermint oil, mostly in enteric-coated capsules, improved overall symptoms more than placebo in several meta-analyses 34568. A randomized controlled trial with a peppermint oil released in the small intestine confirmed this for the total symptom score 50. Abdominal pain also improved more than with placebo in several meta-analyses 345. In children with functional abdominal pain, a peppermint oil capsule relieved the duration, frequency and intensity of pain more than placebo 36. This is contrasted by randomized controlled trials: in children with irritable bowel syndrome, peppermint oil was not more effective than placebo 22. In adults, it missed the primary endpoints, but improved abdominal pain, discomfort and severity as secondary endpoints 24. The evidence is strong, but the individual studies are inconsistent; mainly capsules were tested, not tea, and in children the results are contradictory 2236.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Ingrosso et al. 2022 | meta-analysis · 1,030 participants | Peppermint oil; vs. Placebo | Global IBS symptoms (not improving): improved (RR of not improving = 0.65; 95% CI 0.43-0.98); Abdominal pain (not improving): improved (RR of abdominal pain not improving = 0.76; 95% CI 0.62-0.93); Any adverse event (RR of any adverse event = 1.57; 95% CI 1.04-2.37) |
| 4 Alammar et al. 2019 | meta-analysis · 835 participants | Peppermint oil (PO); vs. Placebo | Global symptom improvement: improved (RR 2.39 [95% CI: 1.93, 2.97], p < 0.00001); Abdominal pain: improved (RR 1.78 [95% CI: 1.43, 2.20], p < 0.00001); Adverse effects (RR 1.40 [95% CI: 0.87, 2.26], p = 0.16) |
| 5 Khanna et al. 2014 | systematic review · 726 participants | Enteric-coated peppermint oil capsules; at least 2 weeks; vs. Placebo | Global improvement of IBS symptoms: improved (relative risk 2.23; 95% confidence interval, 1.78-2.81); Improvement in abdominal pain: improved (relative risk 2.14; 95% confidence interval, 1.64-2.79) |
| 6 Huang et al. 2022 | meta-analysis · 722 participants | Peppermint oil; vs. Placebo | IBS Symptom Severity Scale (IBS-SSS): no difference (MD = 15.35, 95% CI: -25.16-55.86, P = 0.46); IBS quality of life (IBS-QOL): no difference (MD = 0.78, 95% CI: -0.18-1.74, P = 0.11); IBS-Global improvement in symptoms (IBS-GIS): improved (RR = 1.62, 95% CI: 1.20-2.17, P = 0.002) |
| 8 Ford et al. 2008 | meta-analysis · 392 participants | Peppermint oil; at least one week; vs. Placebo | Relative risk of persistent symptoms: improved (0.43, 0.32 to 0.59) |
| 17 Utz et al. 2024 | review | Peppermint oil (essential oil); vs. Guideline recommendations and other phytotherapeutics | Guideline recommendation for pain and flatulence: improved ("strongly recommended") |
| 21 Shen et al. 2009 | review | Peppermint oil; vs. other complementary and alternative therapies | IBS symptoms including abdominal pain: improved |
| 22 Vermeijden et al. 2026 | randomised controlled · 228 participants | Peppermint oil capsules (double-blind) and peppermint sweets (open-label); 182 mg oil or 9.2 mg oil, 2-3 times daily, dose escalation allowed; 8 weeks intervention, 4 weeks follow-up; vs. Placebo (2.0 mg peppermint oil) | Treatment success (≥30% pain reduction): no difference (OR, 1.33; 97.5% CI, 0.58-3.09; P = .44); Treatment success (≥30% pain reduction): no difference (OR, 1.05; 97.5% CI, 0.45-2.44; P = .91); Adequate relief of symptoms: no difference (OR, 1.15; 97.5% CI, 0.54-2.47; P = .68) |
Further studies in this area: 24 26 36 50 82 88 89 90 106 107 109 110 111 112 113 114 115 117 119 121 122 123 128 129 130 132 133 134 136 138 139 140 141 142
Peppermint, Cognition and Alertness: Human Studies
For cognition and alertness, a randomized controlled trial with peppermint tea shows that cognitive performance in a computer-based test battery improved more in healthy adults than with placebo 64. A systematic review on essential peppermint oil as a scent comes to no clear result 13. The evidence is moderate: there are only a few small controlled studies with different forms (tea, essential oil as a scent); it is open how these act with longer use or in people with cognitive impairment.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 13 Nishi et al. 2025 | review | Peppermint (Mentha × piperita L.) essential oil scent | Cognitive effect of peppermint scent: unclear |
| 40 Mahdavikian et al. 2021 | randomised controlled · 105 participants | Inhalation of 3 drops peppermint essential oil; 3 drops per night; 7 nights; vs. lavender oil and aromatic placebo | Fatigue (Fatigue Severity Scale): improved (P < 0.001); Fatigue peppermint vs. lavender: no difference |
| 64 Netzler et al. 2025 | randomised controlled · 25 participants | Peppermint tea, 200 mL; 200 mL tea; short-term (pre-post intervention); vs. Placebo control | Cognitive performance (computerized battery): improved |
| 78 Tang et al. 2021 | controlled · 60 participants | Peppermint odor vs. placebo (air); vs. Peppermint odor vs. placebo; tactile, auditory, combined | Alertness after takeover: improved |
| 100 Lin et al. 2022 | study | Peppermint essential oil; vs. White, red and blue light stimulation | Alpha waves in the prefrontal area: improved; Alpha wave activity in the occipital area: improved |
| 111 Kazemi et al. 2025 | review | Peppermint (leaves, essential oil, extracts) | Improvement in memory and alertness: improved |
Peppermint, Headache and Migraine: Human Studies
The controlled trials in this area concern migraine and chronic headaches in adolescents, not tension-type headache in the narrower sense. In adults with migraine, peppermint oil nasal drops in a randomized controlled trial relieved headaches more than placebo and similarly to lidocaine drops 35. In adolescents with chronic headaches, a foot bath with peppermint oil did not relieve pain more than a foot bath without oil 62. The strength of evidence is low; above all, it is open how peppermint oil acts in tension-type headache.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 20 Lopresti et al. 2020 | review | Menthol/peppermint oil as single ingredient; vs. Placebo or other treatment | Acute treatment of migraine: improved (positive, preliminary findings) |
| 35 Rafieian-Kopaei et al. 2019 | randomised controlled · 120 participants | Peppermint essential oil nasal drops 1.5%; Nasal drops, second dose after 15 min if needed; Follow-up over 2 months; vs. Intranasal lidocaine 4% and placebo | Headache intensity after treatment: improved (P < 0.001); Proportion with considerable response: improved (42.1%); Proportion with decreased headache intensity: improved (40%) |
| 62 Kingsley et al. 2023 | randomised controlled · 46 participants | Foot bath plus peppermint oil; Brief intervention with baseline, mid- and post-intervention measurements; vs. Foot bath without peppermint oil | Subjective pain intensity: no difference |
Peppermint and Physical Performance: Human Studies
In recreational runners, essential peppermint oil in water in a randomized controlled trial prolonged running time to exhaustion compared with placebo 67. In healthy participants, however, peak oxygen uptake and endurance time remained unchanged after several days of intake 68. The strength of evidence is low, especially since the groups with 14 and 7 participants were small and the tested form was the essential oil, not tea, extract or enteric-coated capsules. An uncontrolled study with before-and-after comparison reports better endurance time and performance after essential peppermint oil in mineral water, but without a control group it cannot show a causal relationship 93. Whether peppermint oil reliably prolongs endurance must be clarified by larger studies.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 67 Miranda et al. 2023 | randomised controlled · 14 participants | Peppermint essential oil in water; 0.05 mL oil in 500 mL water, plus 400 mL drink; Run to exhaustion at 70% VO2max; vs. Placebo (water) | Time to exhaustion: improved (109.9 ± 6.9 min in PEO and 98.5 ± 6.2 min in PLA (p = 0.009; effect size: 0.826)) |
| 68 Shepherd et al. 2017 | randomised controlled · 7 participants | Peppermint essential oil (PEP); 10 days; vs. Control, randomised crossover | Peak oxygen uptake: no difference (3.54 vs. 3.52 L/min); Time to exhaustion: no difference (583.33 vs. 587.04 s) |
| 93 Meamarbashi et al. 2013 | study · 12 participants | Mineral water with 0.05 ml peppermint essential oil; 0.05 ml peppermint essential oil in 500 ml water daily; 10 days; vs. Before-after comparison without control group | Time to exhaustion: improved (664.5 ± 114.2 vs. 830.2 ± 129.8 s); Work: improved (78.34 ±32.84 vs. 118.7 ± 47.38 KJ); Power: improved (114.3 ± 24.24 vs. 139.4 ± 27.80 KW) |
Peppermint and Functional Dyspepsia: Human Studies
For functional dyspepsia, peppermint has so far been tested mainly in fixed mixtures with caraway oil or other medicinal plants, whose effect cannot be attributed to peppermint alone. One randomized controlled trial with essential peppermint oil alone involved ventilated intensive care patients with enteral nutrition and showed a reduced gastric residual volume, not the digestive complaints themselves 56. The effect of peppermint tea and of essential peppermint oil without caraway in functional dyspepsia remains open.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 56 Mohammadzadeh et al. 2022 | randomised controlled · 60 participants | Supermint Drop (peppermint essential oil) vs. placebo; 20 drops in 40 ml water, three times daily; 4 days; vs. Placebo | Gastric residual volume (GRV): improved (1.16 (95% confidence interval: 0.75, 1.57) lower) |
| 82 Storr et al. 2022 | cross-sectional study · 1,686 participants | Peppermint oil (compared with hyoscine butylbromide and hyoscine butylbromide+paracetamol); vs. HBB and HBB+paracetamol | Overall effectiveness for gastrointestinal cramps and pain: no difference |
| 104 Pasta et al. 2026 | review | Peppermint-caraway preparation | Symptom improvement: improved |
| 109 Moniruzzaman et al. 2025 | review | Peppermint oil, ginger, STW-5, ZZKZ, Rikkunshito; vs. Placebo-controlled trials | Improvement of gastrointestinal symptoms: improved |
| 111 Kazemi et al. 2025 | review | Peppermint (leaves, essential oil, extracts) | Effectiveness in functional dyspepsia: improved |
| 116 Tursi et al. 2025 | review | STW 5-II, fixed combination of six hydroethanolic herbal extracts; vs. Placebo in several controlled studies | Efficacy in functional dyspepsia: improved (more effective than placebo) |
| 122 Scarpellini et al. 2023 | review | Peppermint oil; vs. classical pharmacological treatments | Treatment of functional dyspepsia: improved |
| 124 Yoon et al. 2022 | review | Peppermint and caraway (combination); vs. Placebo or other CAM | Evidence for efficacy: unclear (limited evidence) |
Further studies in this area: 131 132
Peppermint, Respiratory Tract and Common Cold Symptoms: Human Studies
For respiratory tract and cold complaints, the randomized controlled trial with nebulized essential peppermint oil in healthy participants shows no difference in forced vital capacity, peak expiratory flow, and FEV1/FVC ratio compared with eucalyptus oil, rosemary oil, or no treatment 38. A small study without a control group reports improvements in forced vital capacity, peak expiratory flow, and peak inspiratory flow after mineral water with essential peppermint oil, but this design does not allow causal attribution 93.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 38 Köteles et al. 2018 | randomised controlled · 106 participants | Nebulized peppermint essential oil; 15 minutes; vs. Eucalyptus oil, rosemary oil, or no treatment | Forced vital capacity: no difference; Peak expiratory flow: no difference; FEV1/FVC ratio: no difference |
| 93 Meamarbashi et al. 2013 | study · 12 participants | Mineral water with 0.05 ml peppermint essential oil; 0.05 ml peppermint essential oil in 500 ml water daily; 10 days; vs. Before-after comparison without control group | Forced vital capacity (FVC): improved (4.57 ± 0.90 vs. 4.79 ± 0.84; p < 0.001); Peak expiratory flow rate (PEF): improved (8.50 ± 0.94 vs. 8.87 ± 0.92; p < 0.01); Peak inspiratory flow (PIF): improved (5.71 ± 1.16 vs. 6.58 ±1.08; p < 0.005) |
| 128 Mughal et al. 2022 | review | Peppermint oil, also enteric-coated capsules (Colpermin) | Use in respiratory tract inflammation: unclear |
Peppermint: Further Outcomes in Studies
Inhaled essential peppermint oil relieved pain more than the control, for example after joint replacement and disc surgery and during placement of a venous catheter in cardiac patients 254651. Before injections at the dentist, children with peppermint oil on the mucosa felt less pain than with lidocaine gel or ice 27. In dialysis patients, peppermint gel reduced puncture pain compared with usual care, similar to a cold pack 43. In menstrual pain, peppermint capsules relieved pain similarly to mefenamic acid, but additional painkillers were taken more often 30. Anxiety also decreased more under inhaled peppermint oil than in the control group, for example after operations and in acute coronary syndrome 2537515370. During placement of a venous catheter, no difference was shown for anxiety 46, and in children before dental treatment, peppermint scent acted more weakly than chamomile and lavender 42. The robustness is overall high, but it is based predominantly on small, sometimes non-blinded studies with short follow-up; results apply in each case to the tested form, such as inhalation, topical preparation or enteric-coated capsule, and are not interchangeable.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Wang et al. 2025 | meta-analysis · 2,062 participants | Peppermint extract (among 15 plant substances); vs. Standard treatment | Quality of life: unclear; Fatigue: unclear; Pain: unclear |
| 2 Shetty et al. 2024 | meta-analysis · 1,495 participants | Topical peppermint, partly with lanolin and aloe vera; vs. Lanolin, aloe vera and/or control | Nipple pain: improved; Nipple trauma: improved |
| 5 Khanna et al. 2014 | systematic review · 726 participants | Enteric-coated peppermint oil capsules; at least 2 weeks; vs. Placebo | Adverse events |
| 7 Fang et al. 2025 | meta-analysis · 690 participants | Inhaled essential oils, including peppermint oil; vs. usual care and other essential oils | Sleep quality: unclear |
| 10 Mascarenhas et al. 2025 | meta-analysis | Aromatherapy with essential oils, including peppermint/mint; vs. Conventional treatment, other complementary therapies, or placebo | Maternal anxiety: improved (SMD = -0.67; 95 % CI: -0.95, -0.40); Sleep quality: improved (mean difference = -1.55; 95 % CI: -2.09, -1.01) |
| 11 Pezantes-Orellana et al. 2025 | systematic review | Essential oils, including peppermint oil, in cosmetic formulations | Efficacy for skin conditions: unclear |
| 16 Gonçalves et al. 2024 | systematic review | Peppermint (Mentha piperita) as part of a mixture | Antipruritic effect: improved |
| 18 Tahir et al. 2024 | meta-analysis | Aromatherapy, including peppermint oil (inhalation or massage); vs. Control/no aromatherapy | Pain score in primary dysmenorrhea: improved (SMD -3.19 (CI -5.09, -1.28; I² = 98%)); Pain score (RCTs): improved (− 0.98 (CI-1.40, -0.57; I² = 64%)); Moderate to severe pain: improved (RR: 0.39; CI 0.25, 0.60; I² = 36%) |
Further studies in this area: 19 23 25 27 28 29 30 31 32 33 37 41 42 43 44 45 46 47 48 51 52 53 54 55 59 60 61 62 63 64 65 69 70 71 72 73 74 75 76 77 78 79 81 83 84 86 87 91 92 93 94 95 96 97 98 99 101 102 103 105 108 111 118 120 122 125 126 127 128 132 135
4. How Is Peppermint Dosed? Preparation, Dose and Duration in Studies
The studies mainly tested inhaled or ingested essential peppermint oil, enteric-coated capsules and peppermint extract. Peppermint tea was tested in one controlled trial on cognition. Some studies investigated mixtures with other essential oils or plant extracts, whose results cannot be attributed to peppermint alone. Externally, peppermint oil was tested as a gel on the skin and on the oral mucosa 2743.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Peppermint oil capsules (double-blind) and peppermint sweets (open-label) | 182 mg oil or 9.2 mg oil, 2-3 times daily, dose escalation allowed | 8 weeks intervention, 4 weeks follow-up | 22 |
| Peppermint nutraceutical | 3 mL daily | 3 months intervention, 1 month washout | 23 |
| Small-intestinal-release or ileocolonic-release peppermint oil | 182 mg per day | 8 weeks | 24 |
| Inhalation of peppermint essential oil (aromatherapy) | — | 3 days postoperatively (POD assessment) | 25 |
| Double-blind peppermint oil, placebo, or treatment as usual | — | 6 weeks | 26 |
| topical peppermint gel | three times daily, thin layer on at-risk skin areas | up to 14 days | 28 |
| Lavender-peppermint essential oil pad | — | twenty minutes before biopsy | 29 |
| Peppermint capsule (extract) | — | 3 days from menstruation onset | 30 |
| Peppermint cream | — | up to the fourteenth day | 31 |
| peppermint oil aromatherapy massage | biweekly 15-min knee massage | four weeks, one-month follow-up | 32 |
| Inhalation of peppermint essential oil | three drops of essential oil | 7 days | 33 |
| Inhalation of 10% or 30% peppermint essential oil | 0.2 ml of 10% or 30% peppermint oil | Single application, measured after 10 minutes | 34 |
| Peppermint essential oil nasal drops 1.5% | Nasal drops, second dose after 15 min if needed | Follow-up over 2 months | 35 |
| pH-dependent peppermint oil capsules (Colpermin) | — | 1 month | 36 |
| Inhalation with 2% peppermint oil | 2% peppermint oil, inhalation | before induction, preoperatively, immediately after extubation | 37 |
5. Is Peppermint Safe? Side Effects in Studies
The side effects were mostly mild and temporary, most commonly heartburn 5. Two meta-analyses found more adverse events with peppermint oil 36, another found no confirmed difference 4. In several controlled trials, peppermint oil was well tolerated, sometimes with no differences from placebo 450.
| Study | Reported side effects |
|---|---|
| 3 Ingrosso et al. 2022 | Adverse events more frequent with peppermint oil (RR 1.57) |
| 4 Alammar et al. 2019 | No difference: PO 9.3% vs. placebo 6.1%, RR 1.40 (95% CI 0.87–2.26), p = 0.16 |
| 5 Khanna et al. 2014 | More adverse events, mostly mild and transient; most common heartburn |
| 6 Huang et al. 2022 | Peppermint oil group had significantly more adverse events than placebo |
| 10 Mascarenhas et al. 2025 | Described as safe and effective, no specific data |
| 11 Pezantes-Orellana et al. 2025 | Safety assessed, but no specific data on peppermint |
| 17 Utz et al. 2024 | Safety and tolerability rated predominantly very good to acceptable |
| 22 Vermeijden et al. 2026 | Adverse events mild and infrequent |
| 24 Weerts et al. 2020 | Mild adverse events more common in both peppermint oil groups (P < .005) |
| 25 Liu et al. 2025 | Adverse events as secondary endpoint, no numbers reported |
| 26 Ballou et al. 2022 | Extraintestinal symptoms decreased in all groups; most had no new/worse symptoms |
| 30 Masoumi et al. 2016 | Nausea and diarrhea lower than with mefenamic acid |
6. What Remains Open: Limits of the Evidence
- Many studies tested combination products with other active ingredients, so the finding cannot be attributed to peppermint alone.
- Peppermint tea has so far been tested in a controlled way only for cognition; studies on digestion and nausea are still pending.
- The participant numbers of many studies are small, and follow-up is usually short.
- External application and ingestion were investigated separately and are not interchangeable.
- Long-term studies are still pending, and in children with abdominal pain the results are contradictory 2236.
7. Bottom Line: What Is Established About Peppermint
Peppermint has been studied as tea, essential oil, enteric-coated capsules and extract. Nausea and irritable bowel are the best studied: after operations, inhaled peppermint oil relieved nausea more than the control 485773. For irritable bowel, peppermint oil capsules outperformed placebo for overall symptoms and abdominal pain in several meta-analyses 345. For endurance, two small studies contradict each other 6768; for migraine, peppermint oil nasal drops relieved headache more than placebo 35. For cognition and alertness, one randomized controlled trial with peppermint tea found better scores in healthy adults 64.
The side effects were mostly mild and temporary, most commonly heartburn 5; several meta-analyses found more adverse events with peppermint oil than with placebo 356. Overall, the data are broad, but many studies tested mixtures and small groups, and peppermint tea was not tested in a controlled way in most areas.
Frequently Asked Questions
How well has Peppermint been studied in humans?
We evaluated 146 human studies on Peppermint, including 55 randomised controlled trials and 17 meta-analyses or systematic reviews; the controlled studies include 4,562 participants in total. As of 24 October 2026.
Does Peppermint help with nausea? What the studies show
Does Peppermint help with irritable bowel syndrome? What the studies show
Does Peppermint help with cognition and alertness? What the studies show
Does Peppermint help with headache and Migraine? What the studies show
Does Peppermint help with physical performance? What the studies show
Does Peppermint help with functional dyspepsia? What the studies show
For which complaints is peppermint best studied?
Does peppermint tea work the same as capsules or oil?
The forms are not interchangeable. Peppermint tea was tested in one randomized controlled trial on cognition and showed better performance in healthy adults there 64. For nausea, irritable bowel and functional digestive complaints, there are no separate controlled tests of peppermint tea.
What should be considered with combination products?
Many studies tested peppermint in combination with other active ingredients, such as essential oils, caraway oil or herbal extracts. The results then apply to the mixture and cannot be attributed to peppermint alone.
Which side effects are known?
Does peppermint help with physical performance or headaches?
There are only a few small studies on this with inconsistent results. In recreational runners, peppermint oil in water prolonged the time to exhaustion compared with placebo 67, in another small study endurance remained unchanged 68. For migraine, peppermint oil nasal drops relieved headache more than placebo and similarly to lidocaine 35.
Sources
- 1Wang L, Xu X, Guo M, Dong Y, Ding H, Hao S et al. · 2025
- 2Shetty AP, Halemani K, Issac A, Thimmappa L, Shashidhara YN, Mathias E et al. · 2024
- 3Ingrosso MR, Ianiro G, Nee J, Lembo AJ, Moayyedi P, Black CJ et al. · 2022
- 4Alammar N, Wang L, Wang L, Saberi B, Nanavati J, Holtmann G et al. · 2019
- 5Khanna R, MacDonald JK, Levesque BG · 2014
- 6Huang Z, Huang X, Wan Y · 2022
- 7Fang CS, Tu YK, Chou FH, Fang CJ, Chang SL · 2025
- 8Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM et al. · 2008
- 9
- 10Mascarenhas VHA, Caroci-Becker A, Nick JM, Sahin S, Drigo RTDC, Riesco ML et al. · 2025
- 11Pezantes-Orellana C, German Bermúdez F, Montalvo J, Packer T, Orellana-Manzano A · 2025
- 12Gergő D, Garmaa G, Tóth-Mészáros A, To UND, Fehérvári P, Harnos A et al. · 2025
- 13Nishi R, Sagiyama K, Fukumoto T, Amitani H, Asakawa A · 2025
- 14Wang JY, Huang HY, Chu WO, Peng TR, Lee MC, Chen SM et al. · 2024
- 15
- 16Gonçalves S, Fernandes L, Caramelo A, Martins M, Rodrigues T, Matos RS · 2024
- 17Utz S, Bittel M, Langhorst J · 2024
- 18Tahir HN, Rehman N, Tahir M, Alotaibi N, Al-Dhubaibi MS, Mohamed NEE et al. · 2024
- 19AlMohammed HI, A Alanazi N, Maghrabi EF, A Alotaibi M · 2022
- 20Lopresti AL, Smith SJ, Drummond PD · 2020
- 21Complementary and alternative medicine for treatment of irritable bowel syndromeShen YH, Nahas R · 2009
- 22Vermeijden NK, van der Feen C, Groeneweg M, Hummel T, Zagers D, Bertrams-Maartens I et al. · 2026
- 23
- 24Weerts ZZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ et al. · 2020
- 25Liu M, Tang H, Zhou Z, Yang M, Shen J, Ji Z et al. · 2025
- 26Ballou S, Hassan R, Nee J, Iturrino J, Rangan V, Cheng V et al. · 2022
- 27Sharma D, Bhat M, Khairwa A, Shekhawat D, Medhi BR, Borah B · 2025
- 28Babamohamadi H, Ansari Z, Nobahar M, Mirmohammadkhani M · 2019
- 29Hancı E, Uslu Y, Arıbal E · 2025
- 30Masoumi SZ, Asl HR, Poorolajal J, Panah MH, Oliaei SR · 2016
- 31Shanazi M, Farshbaf Khalili A, Kamalifard M, Asghari Jafarabadi M, Masoudin K, Esmaeli F · 2015
- 32Momen Arani Z, Zamani B, Barati AM, Zarei M, Mirbagher Ajorpaz N · 2025
- 33Hamzeh S, Safari-Faramani R, Khatony A · 2020
- 34Ahmadi Y, Rezaei J, Rezaei M, Khatony A · 2020
- 35Rafieian-Kopaei M, Hasanpour-Dehkordi A, Lorigooini Z, Deris F, Solati K, Mahdiyeh F · 2019
- 36
- 37Tang H, Liu M, Zhou Z, Liu H, Ji Z, Yang M et al. · 2026
- 38Köteles F, Babulka P, Szemerszky R, Dömötör Z, Boros S · 2018
- 39Kamalvand N, Shamsizadeh M, Tapak L, Azizi A · 2025
- 40Mahdavikian S, Fallahi M, Khatony A · 2021
- 41Mousavi Vahed SH, Afiat M, Dadgar S · 2022
- 42Abdel Rehim YM, Gadallah LK, El-Motayam AK · 2025
- 43Koushki B, Khajeh M, Bagheri H, Talebi SS, Ebrahimi H · 2023
- 44Jafarimanesh H, Akbari M, Hoseinian R, Zarei M, Harorani M · 2020
- 45Parvizi A, Pour Mohammad R, Haddadi S, Kia SR, Akbari M, Yazdanipour MA · 2025
- 46Akbari F, Rezaei M, Khatony A · 2019
- 47Al Moussawi H, Al Khatib M, El Ahmar M, Al Masri H, Leddy A, Akel T et al. · 2017
- 48Cetin N, Kose G, Gokbel A · 2024
- 49Badr EA, Abdalla HM, Gaafer YA, Kamel MY · 2024
- 50Cash BD, Epstein MS, Shah SM · 2016
- 51
- 52Maghami M, Pour-Abbasi MS, Yadollahi S, Maghami M, Azizi-Fini I, Afazel MR · 2024
- 53Soleimani M, Kashfi LS, Mirmohamadkhani M, Ghods AA · 2022
- 54Döner Şİ, Dağ Tüzmen H, Duran B, Sunar F · 2024
- 55
- 56Mohammadzadeh F, bilondi SS, Sahebanmaleki M, Mend JA–, Tavakolizadeh M, Aalami H et al. · 2022
- 57Maghami M, Afazel MR, Azizi-Fini I, Maghami M · 2020
- 58Effect of Aromatherapy with Peppermint Oil on the Severity of Nausea and Vomiting in Pregnancy: A Single-blind, Randomized, Placebo-controlled trialJoulaeerad N, Ozgoli G, Hajimehdipoor H, Ghasemi E, Salehimoghaddam F · 2018
- 59
- 60Moss M, Ho J, Swinburne S, Turner A · 2023
- 61Shah I, Baffy NJ, Horsley-Silva JL, Langlais BT, Ruff KC · 2019
- 62
- 63Sinclair J, Sant B, Du X, Shadwell G, Dillon S, Butters B et al. · 2026
- 64
- 65Okamoto A, Karibe H, Tanaka S, Kato Y, Kawakami T, Okamoto Y et al. · 2024
- 66Demont LM, Patterson A, Reich RR, Mason TM · 2023
- 67Miranda Neto M, Meireles ACF, Alcântara MA, de Magalhães Cordeiro AMT, Silva AS · 2023
- 68Shepherd K, Peart DJ · 2017
- 69Ghasemi F, Nadri Z, Valizadeh F, Mohammadi R, Seifosadat H · 2026
- 70Sharafi H, Hosseinpour A, Hosseini-Amiri M, Khahan-Yazdi I · 2026
- 71Zhou Z, Tang H, Liu M, Ji Z, Yang M, Shen J et al. · 2026
- 72Baek SW, Noh JH, Lee D · 2025
- 73Pashaei S, Akyüz N, Ersoy YE · 2025
- 74
- 75Han JY, Moosvi Z, Duh E, Park S, Albers GC, Samarasena JB et al. · 2021
- 76Nemoto D, Utano K, Isohata N, Endo S, Kumamoto K, Koshimizu TA et al. · 2017
- 77O'Hara FJ, Costigan C, Mc Namara D · 2025
- 78Tang Q, Guo G, Zhang Z, Zhang B, Wu Y · 2021
- 79Dilrukshi EAC, Ogino T, Ishikawa M, Kuroda H, Nomura S · 2024
- 80
- 81Warshaw EM, Peterson MY, DeKoven JG, Adler BL, Pratt MD, Belsito DV et al. · 2025
- 82Storr M, Weigmann H, Landes S, Michel MC · 2022
- 83Ali R, Irfan M, Akram U, Vaince M, Hassan K, Maqsood A et al. · 2021
- 84Mancak M, Koca Çalışkan U · 2023
- 85Brennan JA, Brennan R, Bojka S, Green C, Lane T, Martins C et al. · 2025
- 86
- 87Czarnecki ML, Michlig JR, Norton AM, Stelter AJ, Hainsworth KR · 2022
- 88Linas I, Vavricka SR, Langhorst J, Pohl D, Stracke B, Zimmermann A et al. · 2026
- 89Matsueda K, Fukudo S, Ogishima M, Naito Y, Nakamura S · 2024
- 90Traserra S, Barber C, Alcalá-González LG, Landolfi S, Lange R, Malagelada C et al. · 2024
- 91Love L, Crawford K, Adair C · 2025
- 92Abdelrahman SM, El Samak M, El-Baz LMF, Hanora AMS, Satyal P, Dosoky NS · 2024
- 93Meamarbashi A, Rajabi A · 2013
- 94Pham YL, Yu R, Beauchamp J · 2023
- 95Ruszkiewicz DM, Kiland KJ, Mok Y, Bartolomeu C, Borden SA, Thomas P et al. · 2024
- 96Massenet T, Bosman P, Schleich F, Guiot J, Gridelet G, Henket M et al. · 2026
- 97Sanders G · 2023
- 98METHOD FOR TREATING PATIENTS WITH COMBINED PATHOLOGY OF GASTRODUODENAL AND BILE-EXCRETORY SYSTEMSPETRAKOVA VALENTINA STEPANOVNA, ZADOROZHNAJA NATAL JA ALEKSAND, UGOL NIKOVA OL GA IVANOVNA, BELOBORODOVA EHL VIRA IVANOVNA, BESPALOV ALEKSANDR NIKOLAEVICH, KARYMOVA KIRA NIKOLAEVNA et al. · 2006
- 99Oratz T, Liu K, Jackson P, Gettis M · 2026
- 100Lin S, Wang Y, Wu K, Yu G, Liu C, Su C et al. · 2022
- 101Sindi AM, Hosny KM, Alharbi WS · 2021
- 102Parvataneni S, Vemuri-Reddy S · 2020
- 103
- 104Pasta A, Formisano E, Calabrese F, Navazzotti G, Giannini EG, Savarino V et al. · 2026
- 105Iranitalab M, Ouanounou A · 2026
- 106Pastras P, Aggeletopoulou I, Bali M, Triantos C · 2026
- 107Mohamed FA, Hassan MM, Aboulmagd YM, Attallah KA, Ghaiad HR, El-Shiekh RA et al. · 2026
- 108Mo L, Ye S, Qin Y, Shen H, He H, Hong W et al. · 2026
- 109Moniruzzaman M, Shah A, Morrison M, Koloski N, Gwee KA, Chen M et al. · 2025
- 110Abalo R, Gallego-Barceló P, Gabbia D · 2025
- 111Kazemi A, Iraji A, Esmaealzadeh N, Salehi M, Hashempur MH · 2025
- 112Memel ZN, Shah ND, Beck KR · 2025
- 113Saps M, Arrizabalo S · 2025
- 114Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel SyndromeBor S, Özen H, Kalkan İH, Akyüz F, Çelebi A, Dinçer D et al. · 2025
- 115Marasco G, Cremon C, Salvi D, Meacci D, Dajti E, Colecchia L et al. · 2025
- 116Tursi A, Marinoni B, Privitera AC, Privitera L, Danese S · 2025
- 117Natural Products for the Treatment of Irritable Bowel SyndromeBrigstocke S, Brenner DM · 2025
- 118Gawish AS, ElMofty MS, Jambi S, Felemban D, Ragheb YS, Elsayed SA · 2024
- 119Salvatore S, Carlino M, Sestito S, Concolino D, Agosti M, Pensabene L · 2024
- 120Serra J, Aguilar A, Barba E, Ciriza de Los Ríos C, Garcia Pravia L, Martínez V et al. · 2024
- 121
- 122Scarpellini E, Broeders B, Schol J, Santori P, Addarii M, Boccuto L et al. · 2023
- 123Pop D, Pop RS, Farcău D · 2023
- 124Yoon JY, Ko SJ, Park JW, Cha JM, Cha JM · 2022
- 125Kenda M, Kočevar Glavač N, Nagy M, Sollner Dolenc M · 2022
- 126Sarecka-Hujar B, Szulc-Musioł B · 2022
- 127Hatfield J, Saad S, Housewright C · 2022
- 128
- 129
- 130
- 131Kim YS, Kim JW, Ha NY, Kim J, Ryu HS · 2020
- 132Chumpitazi BP, Kearns GL, Shulman RJ · 2018
- 133SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, NevadaChey WD · 2017
- 134Camilleri M, Boeckxstaens G · 2017
- 135Sanagapalli S, Agnihotri K, Leong R, Corte CJ · 2017
- 136Dimidi E, Rossi M, Whelan K · 2017
- 137Stoicea N, Gan TJ, Joseph N, Uribe A, Pandya J, Dalal R et al. · 2015
- 138Trinkley KE, Nahata MC · 2014
- 139Grundmann O, Yoon SL · 2014
- 140Vanuytsel T, Tack JF, Boeckxstaens GE · 2014
- 141Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths?Wu JC · 2010
- 142Chang HY, Kelly EC, Lembo AJ · 2006
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.